Semaglutide is one of the most talked-about drugs of the decade, but the conversation around it is cluttered with brand names, dose numbers, and competing weight-loss claims. This page steps back from all of that to answer the plain question — what is this thing? — and to map out how the brands, forms, and uses relate to each other. The deep dives on weight loss, side effects, cost, and head-to-head comparisons live on their own pages, linked throughout; here the goal is orientation.
What semaglutide is
Semaglutide is a GLP-1 receptor agonist. That phrase unpacks into something fairly intuitive. GLP-1, or glucagon-like peptide-1, is a hormone your gut releases after you eat. It’s part of the body’s normal “I’ve had a meal” signaling system. Semaglutide is a synthetic, slightly redesigned copy of that hormone, built to switch on the same receptors — an agonist is a molecule that activates a receptor rather than blocking it.
Chemically, semaglutide is a peptide: a short chain of amino acids. Natural GLP-1 breaks down in the body within minutes, which would make it useless as a once-weekly medicine. The central innovation behind semaglutide is a set of structural modifications — including a fatty-acid chain that lets it bind to albumin, a protein in the blood — that protect it from rapid breakdown and stretch its half-life to roughly a week. That single design choice is what makes a weekly injection (or, in pill form, a daily tablet) possible.
Note: Because semaglutide is technically a peptide, you’ll sometimes see it lumped in with “research peptides” like BPC-157 or TB-500. Resist that grouping. Those compounds are unapproved and largely unstudied in humans; semaglutide is an FDA-approved prescription drug tested in tens of thousands of people. The word “peptide” describes the molecule’s shape, not its evidence or its legal standing.
Semaglutide is made by the Danish company Novo Nordisk, which holds the core patents. It is a prescription-only medicine in the United States — there is no over-the-counter or “supplement” version of the real drug, and products marketed that way are not semaglutide.
How it works, at a high level
When semaglutide activates GLP-1 receptors, several things happen at once, and they explain why one drug ended up approved for such different-sounding conditions.
It prompts the pancreas to release insulin, but only when blood sugar is elevated — a glucose-dependent effect, which is why semaglutide carries a relatively low risk of dangerous low blood sugar on its own. It dials down glucagon, a hormone that raises blood sugar. It slows the rate at which the stomach empties, so food stays with you longer. And it acts on appetite-regulating centers in the brain, reducing hunger and the background “food noise” many people describe.
The metabolic effects (insulin, glucagon) are what make it a diabetes drug. The appetite and gastric-emptying effects are what make it a weight-loss drug. It’s the same molecule doing both jobs through the same receptor — the reason the diabetes brand and the weight-loss brand are chemically identical. The mechanics of how this produces sustained weight loss, and the candidacy and long-term-maintenance questions that come with it, are covered on the weight-loss page.
One molecule, several brands — the map
This is where most confusion starts. Semaglutide is sold under more than one brand name, in more than one form, for more than one condition. The brand on the box tells you the approved use and the approved dose range, not a different drug. Here’s the lay of the land as of 2026.
Ozempic is the injectable form approved for type 2 diabetes, with added indications for reducing the risk of major cardiovascular events and, separately, for slowing kidney-disease progression in eligible patients. It’s a once-weekly shot.
Wegovy is the injectable form approved for chronic weight management — for adults with obesity, or with overweight plus a weight-related condition, and for adolescents aged 12 and up. It uses the same molecule as Ozempic but titrates to a somewhat higher maintenance dose, reflecting its different purpose. Over time Wegovy has also picked up an approval for cardiovascular risk reduction in people with established heart disease, and in 2025 an approval for MASH (metabolic dysfunction-associated steatohepatitis, a serious fatty-liver condition). The full breadth of these uses is graded on the benefits page.
The oral forms add another layer. An oral semaglutide tablet has been available for type 2 diabetes since 2019 (originally branded Rybelsus). In December 2025 the FDA approved a higher-strength 25 mg oral version for chronic weight management — the first GLP-1 pill for obesity — launched in early 2026 and marketed as oral Wegovy. Around the same time, Novo Nordisk began consolidating its oral diabetes tablet under the Ozempic name and phasing out the Rybelsus brand to reduce confusion. The practical takeaway: there are now both injectable and pill versions, and the brand naming is being unified around Ozempic (diabetes) and Wegovy (weight), but the underlying drug is semaglutide throughout.
If your only question is which brand or form is right for a given person, that’s a decision page, not an identity page — see Ozempic vs Wegovy for the brand split and the compounded vs brand page for the product-form choice. The point here is simply that “Ozempic,” “Wegovy,” “Rybelsus,” “the pill,” and “the shot” are all routes to the same active molecule.
Note on doses: The brands differ in their approved dose ranges — the weight-management brand reaches a higher maintenance dose than the diabetes brand, and the pill is dosed differently from the injection because far less of an oral dose is actually absorbed. Specific numbers and how titration works are a clinician’s call and are discussed as a topic, not a protocol, on the dosage page. This site never publishes a self-dosing schedule.
What the evidence actually shows
Here semaglutide stands apart from most compounds covered on this site, and it’s worth stating plainly. The wellness peptides elsewhere in this library — the healing peptides, the growth-hormone secretagogues — are characterized by thin or absent human evidence. Semaglutide is the opposite. It is one of the most thoroughly trialed drugs in modern metabolic medicine.
Its approvals rest on large, randomized, placebo-controlled trials: the SUSTAIN program for blood-sugar control in diabetes, the STEP program for weight management, the SELECT trial for cardiovascular outcomes, the FLOW trial for kidney outcomes, the SOUL trial for cardiovascular risk with the oral form, and the OASIS program behind the oral weight-loss approval. These are not small pilot studies or animal data; several enrolled thousands of participants and followed them for years.
That doesn’t make semaglutide magic or risk-free. Its benefits are real and measured, but they’re averages across a wide spread of individual responses, the effects largely persist only while the drug is taken, and it carries genuine side effects and contraindications. Those nuances — the realistic numbers, who shouldn’t take it, what monitoring looks like — are spread across the benefits, weight-loss, and side-effects pages. The honest one-line summary for this page is: the effects are well-established, which is exactly why expectations should be calibrated to the trial averages rather than the testimonials.
Its US status in 2026
Because this site also covers unapproved peptides caught up in the FDA’s compounding-category reclassification, it’s important to be clear that semaglutide lives in a completely different regulatory world. It is an approved drug. It is not on the Category 1/Category 2 compounding lists, it is not part of the July 2026 advisory-committee review of compounds like BPC-157 and TB-500, and its legality as a prescribed medicine has never been in question.
The semaglutide news of 2025 and 2026 was about supply and compounding, not approval. The FDA declared the semaglutide shortage resolved in February 2025. During the shortage, federal law had allowed compounding pharmacies to make copies of the drug; once the shortage ended, that allowance wound down. The enforcement deadlines for mass-produced compounded semaglutide passed during 2025 and into early 2026, and by the first part of 2026 most large-scale compounding had stopped. Brand Ozempic and Wegovy are now the standard route. Narrow, genuinely patient-specific compounding survives only in limited circumstances — for example, a documented clinical need the approved product can’t meet — and that’s a far smaller door than the shortage-era market was. The legal detail and what it means for access sit on the compounded vs brand page; this is current as of the date above and the compounding landscape continues to shift.
How people access it legally
For most people, getting semaglutide means a prescription for brand Ozempic or Wegovy, obtained through a primary-care provider, an endocrinologist or obesity-medicine clinic, or a legitimate telehealth service that connects you with a licensed prescriber. Insurance coverage varies enormously — diabetes use is more commonly covered than weight-loss use — and self-pay programs from the manufacturer have brought cash prices down considerably from where they were a couple of years ago. The mechanics of routes, prescriptions, and pricing are covered on the how-to-get page and the cost pages.
What’s not a legitimate route is buying “semaglutide” from a research-chemical vendor or importing it from overseas. Products sold that way are not the FDA-approved drug, their actual contents and concentration are unverified, and self-injecting an unverified GLP-1 — which is what a self-measured vial amounts to — is the kind of risk this site consistently flags. The broader legal framework for peptides, including where the gray-market lines fall, is laid out in the legality pillar and the foundational what-are-peptides overview.
Where to go next
If this page has done its job, you now know that semaglutide is a single, FDA-approved GLP-1 molecule sold under a handful of brands and in two forms, with a deep clinical evidence base behind it. From here:
- For how it produces weight loss and who it’s for, see semaglutide for weight loss.
- For the full range of approved and emerging benefits, see semaglutide benefits.
- For choosing between the brands, see Ozempic vs Wegovy.
- For how it stacks up against tirzepatide, see semaglutide vs tirzepatide.
- For the bigger metabolic picture, see the GLP-1 weight-loss guide.
Frequently asked questions
Is semaglutide the same as Ozempic and Wegovy?
Yes. Semaglutide is the active drug; Ozempic and Wegovy are brand names for it made by Novo Nordisk. They differ mainly in their FDA-approved use and approved dose range, not in the molecule itself. Ozempic is approved for type 2 diabetes (plus cardiovascular and kidney risk reduction); Wegovy is approved for chronic weight management (plus cardiovascular risk and, more recently, a liver condition called MASH).
Is semaglutide a peptide?
Yes, in the chemical sense — it's a chain of amino acids modified to last about a week in the body. But it isn't a 'research peptide' like BPC-157 or TB-500. It's a fully FDA-approved prescription drug studied in tens of thousands of patients, which is a very different category.
Is semaglutide available as a pill?
Yes. An oral tablet has been approved for type 2 diabetes since 2019, and in December 2025 the FDA approved an oral 25 mg version (oral Wegovy) for chronic weight management. The injectable forms remain the most widely used.
Is semaglutide FDA-approved in 2026?
Yes, across multiple brands and uses. This is the key difference from most compounds on this site. The 2025-2026 news around semaglutide was about supply and compounding — the shortage was declared resolved and mass-compounded copies were phased out — not about the drug's approval status, which is settled.
Can I still get compounded semaglutide?
Far less easily than during the shortage. After the FDA declared the shortage resolved in February 2025, the windows for mass compounding closed in 2026. Brand Ozempic and Wegovy are now the standard route; narrow, patient-specific compounding survives only in limited cases. See the compounded-vs-brand page for detail.